{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:02:59Z","timestamp":1790370179235,"version":"4.1.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.08.021","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:33:38Z","timestamp":1790368418000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7\u201312"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9822","authenticated-orcid":false,"given":"Ahmed M.","family":"Elalfy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.08.021_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2026.01.015","article-title":"Updated 5-year survival results from PURE-01, a phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer","volume":"90","author":"Tateo","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.08.021_b0010","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.08.021_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.626748","article-title":"PD-L2 is constitutively expressed in normal and malignant urothelium","volume":"11","author":"Dowell","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.08.021_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00151","article-title":"PD-L2 landscape and correlation with outcome: an immunomic analysis","volume":"3","author":"Patwari","year":"2026","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.eururo.2026.08.021_b0025","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1016\/S2666-1683(25)01691-X","article-title":"SMAD7 and NF-\u03baB outperform PD-L2 as prognostic biomarkers in muscle-invasive bladder cancer: a 99-patient cohort study","volume":"81","author":"Elalfy","year":"2025","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826023729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826023729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:33:39Z","timestamp":1790368419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826023729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":5,"alternative-id":["S0302283826023729"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.08.021","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7\u201312","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}